BABAM2-AS1: A Drug Target / Disease Biomarker (G100302650)

Target Name: BABAM2-AS1

NCBI ID: G100302650

BABAM2-AS1

Other Name(s): BRE-AS1 | BABAM2 antisense RNA 1

BABAM2-AS1: A Drug Target / Disease Biomarker

BABAM2-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the BABAM2 family of proteins, which are known for their role in cell signaling and inflammation. While the exact function of BABAM2-AS1 is not yet fully understood, research has shown that it is involved in a variety of physiological processes, including cell migration, invasion, and angiogenesis.

One of the most promising aspects of BABAM2-AS1 is its potential as a drug target. BABAM2-AS1 has been shown to play a role in the regulation of cell proliferation and survival, as well as in the development of cancer. Researchers have also found that BABAM2-AS1 is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, BABAM2-AS1 has also been shown to be a valuable biomarker for a variety of diseases. For example, studies have shown that BABAM2-AS1 is often reduced in the brains of individuals with Alzheimer's disease, and that it is also decreased in the hearts of individuals with heart failure. These findings suggest that BABAM2-AS1 may be a useful diagnostic or therapeutic target for these diseases.

While more research is needed to fully understand the role of BABAM2-AS1 in these diseases, it is clear that it is an important protein that is involved in a variety of physiological processes. As such, BABAM2-AS1 is a promising candidate for further study as a drug target or biomarker.

Protein Name: BABAM2 Antisense RNA 1

The "BABAM2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BABAM2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets